Literature DB >> 324279

Significance of antimicrobial synergism for the outcome of gram negative sepsis.

J Klastersky, F Meunier-Carpentier, J M Prevost.   

Abstract

Amikacin plus penicillin (A+P) was compared to amikacin plus carbenicillin (A+C) in a double-blind study. Therapy with one of these combinations was given, as soon as servere infection was suspected, to 117 patients with proved gram negative infection, none of whom was granulocytopenic. Gram negative bacteremia was documented retrospectively in 52 patients; 25 had received A+P and 27 had been treated with A+C. All the isolated gram negative pathogens were sensitive to amikacin (MIC less than 12 microng/ml). In the A+P group, 55 per cent of the patients responded favorably while in the A+C group 63 per cent did respond; the difference was more striking for bacteremic patients: 52 per cent responded in the A+P group and 70 per cent in the A+C group. This difference, however, was not statistically significant. The outcome of patients whose infection was treated by synergistic combinations against the offending pathogen was better (66 per cent) than that observed in patients who received nonsynergistic combinations (48 per cent) (p less than 0.05). Once again the results were more striking in the bacteremic patients (p less than 0.01). A favorable outcome was associated also with a high (larger than or equal to 1/8) bactericidal activity of the diluted serum of the treated patient against the offending pathogen (p less than 0.05). This study suggests that the optimal therapy in gram negative septicemia might be the administration of synergistic combinations of antibiotics.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324279     DOI: 10.1097/00000441-197703000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  41 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 3.  Serum bactericidal test.

Authors:  C W Stratton
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.

Authors:  R L Baker; R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

8.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Authors:  M A Buesing; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

9.  Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

Authors:  J Klastersky; L Coppens; F Meunier-Carpentier; A P Menday
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

10.  Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Cheng-Yi Chen; Wen-Hwei Chen; Chong-Jen Yu; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.